NASDAQ:COLL Collegium Pharmaceutical (COLL) Stock Price, News & Analysis → How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad) Free COLL Stock Alerts $35.94 +1.20 (+3.45%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$34.92▼$36.5150-Day Range$31.76▼$40.9152-Week Range$20.83▼$40.95Volume618,658 shsAverage Volume324,787 shsMarket Capitalization$1.18 billionP/E Ratio30.46Dividend YieldN/APrice Target$39.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Collegium Pharmaceutical alerts: Email Address Collegium Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside8.5% Upside$39.00 Price TargetShort InterestBearish23.28% of Float Sold ShortDividend StrengthN/ASustainability-2.78Upright™ Environmental ScoreNews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth9.59%From $5.63 to $6.17 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.15 out of 5 starsMedical Sector746th out of 909 stocksPharmaceutical Preparations Industry346th out of 425 stocks 1.3 Analyst's Opinion Consensus RatingCollegium Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted23.28% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently increased by 1.57%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCollegium Pharmaceutical has received a 26.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Tapendatol" and "Oxycodone" products. See details.Environmental SustainabilityThe Environmental Impact score for Collegium Pharmaceutical is -2.78. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Collegium Pharmaceutical this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for COLL on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.98% of the stock of Collegium Pharmaceutical is held by insiders. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Collegium Pharmaceutical are expected to grow by 9.59% in the coming year, from $5.63 to $6.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is 30.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is 30.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 167.00.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 6.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. About Collegium Pharmaceutical Stock (NASDAQ:COLL)Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Read More COLL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COLL Stock News HeadlinesApril 24, 2024 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Upgraded to Strong-Buy at StockNews.comApril 23, 2024 | money.usnews.comCollegium Pharmaceutical IncApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."April 12, 2024 | markets.businessinsider.comOptimistic Buy Rating for Collegium Pharmaceutical: Growth and Market Position AnalysisApril 11, 2024 | markets.businessinsider.comCritical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To KnowApril 11, 2024 | globenewswire.comCollegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026April 9, 2024 | finance.yahoo.comCollegium Pharmaceutical (COLL) Stock Sinks As Market Gains: What You Should KnowApril 4, 2024 | bizjournals.comNovan is gone. But its lead drug lives on with new companyApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."April 3, 2024 | markets.businessinsider.comLigand Pharmaceuticals Announces Launch Of Pelthos; Scott Plesha To Assume Leadership Of PelthosApril 3, 2024 | finance.yahoo.comCollegium to Participate in 23rd Annual Needham Virtual Healthcare ConferenceMarch 23, 2024 | wsj.comCollegium Pharmaceutical Inc.March 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for KalVista Pharmaceuticals on Strong Phase 3 Results and Solid Financial PositionMarch 5, 2024 | finance.yahoo.comCOLL Mar 2024 50.000 callMarch 4, 2024 | insidermonkey.com5 Best Small Cap Pharma Stocks to Invest InFebruary 29, 2024 | finance.yahoo.comInsider Sell: EVP & Chief Commercial Officer Scott Dreyer Sells 10,000 Shares of Collegium ...February 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Protagonist Therapeutics (PTGX) and Viridian Therapeutics (VRDN)February 27, 2024 | finance.yahoo.comThis Unsung Pharmaceutical Stock In The IBD 50 Hit A Buy Zone. Here's Why.February 26, 2024 | seekingalpha.comCollegium Pharmaceutical Q4: The Beat Goes OnFebruary 25, 2024 | msn.comNasdaq Closes In On All-Time High; Carvana Spikes On Earnings While Nvidia Vaults Above 800February 24, 2024 | finance.yahoo.comCollegium Pharmaceutical Full Year 2023 Earnings: EPS Beats ExpectationsFebruary 23, 2024 | markets.businessinsider.comWhere Collegium Pharmaceutical Stands With AnalystsFebruary 23, 2024 | insidermonkey.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2023 Earnings Call TranscriptFebruary 23, 2024 | finance.yahoo.comQ4 2023 Collegium Pharmaceutical Inc Earnings CallFebruary 22, 2024 | benzinga.comRecap: Collegium Pharmaceutical Q4 EarningsFebruary 22, 2024 | finance.yahoo.comCollegium Pharmaceutical Inc Reports Record Earnings for Q4 and Full-Year 2023February 22, 2024 | seekingalpha.comCollegium Pharmaceutical, Inc. 2023 Q4 - Results - Earnings Call PresentationSee More Headlines Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/24/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:COLL CUSIPN/A CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees197Year FoundedN/APrice Target and Rating Average Stock Price Target$39.00 High Stock Price Target$40.00 Low Stock Price Target$37.00 Potential Upside/Downside+8.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.18 Trailing P/E Ratio30.46 Forward P/E Ratio6.38 P/E GrowthN/ANet Income$48.15 million Net Margins8.50% Pretax Margin13.36% Return on Equity107.39% Return on Assets17.07% Debt Debt-to-Equity Ratio2.48 Current Ratio1.17 Quick Ratio1.10 Sales & Book Value Annual Sales$566.77 million Price / Sales2.07 Cash Flow$11.09 per share Price / Cash Flow3.24 Book Value$5.99 per share Price / Book6.00Miscellaneous Outstanding Shares32,710,000Free Float31,404,000Market Cap$1.18 billion OptionableOptionable Beta1.03 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael Thomas Heffernan B.S. Pharm (Age 60)R.Ph., Co-Founder & Chairman Comp: $110kMr. Joseph J. Ciaffoni (Age 52)President, CEO & Director Comp: $1.69MMs. Colleen Tupper (Age 48)Executive VP & CFO Comp: $848.29kMs. Shirley R. Kuhlmann (Age 40)Executive VP, General Counsel, Chief Administrative Officer & Secretary Comp: $842.9kMr. Scott Dreyer (Age 52)Executive VP & Chief Commercial Officer Comp: $746.58kDr. Thomas B. Smith FAAFP (Age 63)M.D., Executive VP & Chief Medical Officer Comp: $692.91kDr. Christopher Shayne James M.D.Vice President of Investor RelationsMr. Bart J. DunnExecutive Vice President of Strategy & Corporate DevelopmentMr. Scott SudduthHead of Technical OperationsMore ExecutivesKey CompetitorsGemini TherapeuticsNASDAQ:GMTXDeciphera PharmaceuticalsNASDAQ:DCPHAbCellera BiologicsNASDAQ:ABCLPieris PharmaceuticalsNASDAQ:PIRSMirum PharmaceuticalsNASDAQ:MIRMView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Sold 274,989 shares on 4/24/2024Ownership: 0.217%Nations Financial Group Inc. IA ADVBought 9,936 shares on 4/23/2024Ownership: 0.030%Allspring Global Investments Holdings LLCSold 424 shares on 4/18/2024Ownership: 0.139%Los Angeles Capital Management LLCSold 4,586 shares on 4/5/2024Ownership: 0.206%HighPoint Advisor Group LLCBought 16,685 shares on 3/26/2024Ownership: 0.052%View All Insider TransactionsView All Institutional Transactions COLL Stock Analysis - Frequently Asked Questions Should I buy or sell Collegium Pharmaceutical stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COLL shares. View COLL analyst ratings or view top-rated stocks. What is Collegium Pharmaceutical's stock price target for 2024? 5 Wall Street analysts have issued twelve-month price targets for Collegium Pharmaceutical's shares. Their COLL share price targets range from $37.00 to $40.00. On average, they predict the company's stock price to reach $39.00 in the next year. This suggests a possible upside of 8.5% from the stock's current price. View analysts price targets for COLL or view top-rated stocks among Wall Street analysts. How have COLL shares performed in 2024? Collegium Pharmaceutical's stock was trading at $30.78 at the start of the year. Since then, COLL shares have increased by 16.8% and is now trading at $35.94. View the best growth stocks for 2024 here. When is Collegium Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our COLL earnings forecast. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announced its quarterly earnings data on Thursday, February, 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.20 by $0.25. The specialty pharmaceutical company earned $149.75 million during the quarter, compared to the consensus estimate of $147.66 million. Collegium Pharmaceutical had a trailing twelve-month return on equity of 107.39% and a net margin of 8.50%. What ETFs hold Collegium Pharmaceutical's stock? ETFs with the largest weight of Collegium Pharmaceutical (NASDAQ:COLL) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH), Pacer US Small Cap Cash Cows 100 ETF (CALF), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH). What guidance has Collegium Pharmaceutical issued on next quarter's earnings? Collegium Pharmaceutical issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $580.0 million-$595.0 million, compared to the consensus revenue estimate of $583.5 million. What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO? 6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH). When did Collegium Pharmaceutical IPO? Collegium Pharmaceutical (COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. Who are Collegium Pharmaceutical's major shareholders? Collegium Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.22%), Los Angeles Capital Management LLC (0.21%), Allspring Global Investments Holdings LLC (0.14%) and Nations Financial Group Inc. IA ADV (0.03%). Insiders that own company stock include Colleen Tupper, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann. View institutional ownership trends. How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:COLL) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
